Radium-223 dichloride in clinical practice: a review

Luigia Florimonte, Luca Dellavedova, Lorenzo Stefano Maffioli

Research output: Contribution to journalReview articlepeer-review


The onset of skeletal metastases is typical of advanced-stage prostate cancer and requires a multidisciplinary approach to alleviate bone pain and try to delay disease progression. The current therapeutic armamentarium includes conventional analgesics, chemotherapeutic agents, immunotherapy, androgen-deprivation therapy, osteoclast inhibitors (bisphosphonates, denosumab), surgical interventions, external-beam radiotherapy and radionuclide metabolic therapy. Many studies in recent decades have demonstrated the efficacy of various radiopharmaceuticals, including strontium-89 and samarium-153, for palliation of pain from diffuse skeletal metastases, but no significant benefit in terms of disease progression and overall survival has been shown. The therapeutic landscape of metastatic skeletal cancer significantly changed after the introduction of radium-223, the first bone-homing radiopharmaceutical with disease-modifying properties. In this paper we extensively review the literature on the use of radium-223 dichloride in metastatic castration-resistant prostate cancer.

Original languageEnglish
Pages (from-to)1896-1909
Number of pages14
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Issue number10
Publication statusPublished - Sep 1 2016


  • Bone metastasis
  • Overall survival
  • Radium-223 dichloride
  • α-Emitters

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Radium-223 dichloride in clinical practice: a review'. Together they form a unique fingerprint.

Cite this